Auro Peptides is an API manufacturer based in India. It holds 14 active US drug master files and 2 valid CEPs across a filed portfolio of 14 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 16 February 2024 as NAI. Customs aggregates show $545K of exports covering 98 molecules to 7 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Kandi Mandal, India | Not on file |
| Sangareddy District, India | 3010923869 |
| Molecule | Regulators | Docs |
|---|---|---|
| Desmopressin | EDQM, US FDA | 2 |
| Octreotide | EDQM, US FDA | 2 |
| Vasopressin | SFDA (Saudi Arabia), US FDA | 2 |
| Degarelix | US FDA | 1 |
| Etelcalcetide | US FDA | 1 |
| Ganirelix | US FDA | 1 |
| Glatiramer | US FDA | 1 |
| Icatibant | US FDA | 1 |
| Leuprolide | US FDA | 1 |
| Linaclotide | US FDA | 1 |
| Liraglutide | US FDA | 1 |
| Plecanatide | US FDA | 1 |
| Semaglutide | US FDA | 1 |
| Teriparatide | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $43 | 2 |
| 2025 | Not reported | $545K | 7 |
| 2024 | Not reported | $407K | 8 |
| 2023 | Not reported | $2.3M | 9 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Auro Peptides comes back tiered against every other supplier able to file there.
Start for free